immatics has its roots at the University of Tuebingen’s Department of Immunology. The company, which was established in 2000, capitalizes on groundbreaking discoveries investigating the role of tumor-associated peptides (TUMAPs) and their interaction with the body’s own natural defense, the immune system.
- 3Q/2000 Inception
- 3Q/2002 First publication on the XPRESIDENT Drug Discovery Engine by Weinschenk et al.
- 1Q/2004 Series A financing (total € 14m)
- 4Q/2005 First product (IMA901) enters phase I
- 3Q/2006 Completion of phase I
- 1Q/2007 Series B financing (€ 40m)
- 2Q/2007 First product (IMA901) enters phase II
- 2Q/2008 Second product (IMA910) enters phase I/II
Today, immatics has a staff of more than 60 skilled and experienced employees who are focused on the rapid transition of our product candidates from drug discovery and pre-clinical research to clinical development.
- Dr. Harpreet Singh
- Dr. Niels Emmerich
- Dr. Toni Weinschenk
- Prof. Dr. Hans Georg Rammensee
- Prof. Dr. Hansjörg Schild
- Prof. Dr. Peter Brossart